Sznurkowski Jacek J, Rys Janusz, Kowalik Artur, Zolciak-Siwinska Agnieszka, Bodnar Lubomir, Chudecka-Glaz Anita, Blecharz Pawel, Zielinska Aleksandra, Marszalek Andrzej, Bidzinski Mariusz, Sawicki Wlodzimierz
Department of Surgical Oncology, Medical University of Gdansk, ul. Smoluchowskiego 17, 80-214 Gdańsk, Poland.
Department of Tumor Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków Branch, 44-102 Kraków, Poland.
J Clin Med. 2023 Feb 13;12(4):1480. doi: 10.3390/jcm12041480.
Due to the increasing amount of published data suggesting that endometrial carcinoma is a heterogenic entity with possible different treatment sequences and post-treatment follow-up, the Polish Society of Gynecological Oncology (PSGO) has developed new guidelines.
to summarize the current evidence for diagnosis, treatment, and follow-up of endometrial carcinoma and to provide evidence-based recommendations for clinical practice.
The guidelines have been developed according to standards set by the guideline evaluation tool AGREE II (Appraisal of Guidelines for Research and Evaluation). The strength of scientific evidence has been defined in agreement with The Agency for Health Technology Assessment and Tariff System (AOTMiT) guidelines for scientific evidence classification. The grades of recommendation have been based on the strength of evidence and the level of consensus of the PSGO development group.
Based on current evidence, both the implementation of the molecular classification of endometrial cancer patients at the beginning of the treatment sequence and the extension of the final postoperative pathological report of additional biomarkers are needed to optimize and improve treatment results as well as to pave the route for future clinical trials on targeted therapies.
由于越来越多已发表的数据表明子宫内膜癌是一种具有可能不同治疗顺序和治疗后随访的异质性实体，波兰妇科肿瘤学会（PSGO）制定了新的指南。
总结子宫内膜癌诊断、治疗和随访的当前证据，并为临床实践提供基于证据的建议。
这些指南是根据指南评估工具AGREE II（研究与评估指南评估）设定的标准制定的。科学证据的强度已根据卫生技术评估与收费系统局（AOTMiT）科学证据分类指南进行定义。推荐等级基于证据强度和PSGO制定小组的共识水平。
基于当前证据，在治疗序列开始时对子宫内膜癌患者进行分子分类以及扩展最终术后病理报告中的其他生物标志物，对于优化和改善治疗结果以及为未来靶向治疗的临床试验铺平道路都是必要的。
